<DOC>
	<DOCNO>NCT01118689</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , maximum tolerate dose pharmacokinetics MLN0128 patient Relapsed Refractory Multiple Myeloma Waldenstrom Macroglobulinemia</brief_summary>
	<brief_title>Dose Escalation Study MLN0128 Relapsed Refractory Multiple Myeloma Waldenstrom Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Age ≥18 year , include male female ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 ; Life expectancy ≥3 month ; Does diabetes normal fast serum glucose fast triglyceride ≤ 300 mg/dL For woman childbearing potential , negative serum pregnancy test within 14 day prior first study drug administration use physicianapproved method birth control 30 day prior first study drug administration 30 day follow last study drug administration ; Male subject must surgically sterile must agree use physicianapproved contraception study 30 day follow last study drug administration ; Ability swallow oral medication ; Ability understand willingness sign inform consent form prior initiation study procedure ; Have receive prior cancer therapy investigational therapy within 2 week prior first administration study drug . Known impaired cardiac function clinically significant cardiac disease HIV infection ; Failed recover reversible effect prior anticancer therapy : Pregnancy ( positive serum urine pregnancy test ) breast feeding ; Malabsorption due prior gastrointestinal ( GI ) surgery , GI disease ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>